Anthera Pharmaceuticals to Present at Rodman & Renshaw’s 18th Annual Global Investment Conference Print
By GLOBE NEWSWIRE   
Wednesday, 06 September 2017 02:30

HAYWARD, Calif., Sept. 06, 2017 (GLOBE NEWSWIRE)

HAYWARD, Calif., Sept. 06, 2017 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH), a biopharmaceutical company focused on developing and commercializing products to treat serious and life-threatening diseases, including exocrine pancreatic insufficiency and IgA nephropathy, announced today that Craig Thompson, President & Chief Executive Officer, will present a corporate update at Rodman & Renshaw’s 18th Annual Global Investment Conference.

The presentation will be at 10:25 AM ET, September 12th, at the Lotte New York Palace Hotel in New York.

The audio portion of the presentation will be accessible through the company’s Investors page at www.anthera.com/investors following the presentation.

About Anthera Pharmaceuticals, Inc.

Anthera Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products to treat serious and life-threatening diseases, including exocrine pancreatic insufficiency and IgA nephropathy. Additional information on Anthera can be found at www.anthera.com.

Safe Harbor Statement

Any statements contained in this press release that refer to future events or other non-historical matters, including statements that are preceded by, followed by, or that include such words as "estimate," "intend," "anticipate," "believe," "plan," "goal," "expect," "project," or similar statements, are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on Anthera's expectations as of the date of this press release and are subject to certain risks and uncertainties that could cause actual results to differ materially as set forth in Anthera's public filings with the SEC, including Anthera's Quarterly Report on Form 10-Q for the quarter ended June 30, 2017.  Anthera disclaims any intent or obligation to update any forward-looking statements, whether because of new information, future events or otherwise, except as required by applicable law.

Contact Information  CONTACT: Investor Relations of Anthera Pharmaceuticals, Inc. ir@anthera.com  For Media Inquiries: Srikant Ramaswami  rbb Communications  srikant.ramaswami@rbbcommunications.com 718-710-1350  www.twitter.com/antherapharma https://www.facebook.com/antherapharma/  https://www.linkedin.com/company/anthera-pharmaceuticals 

Primary Logo




BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and
investor relation services from various entities and

Error. Page cannot be displayed. Please contact your service provider for more details. (11)

firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!
  BMR:1